نتایج جستجو برای: cost cancer drugs nhccd
تعداد نتایج: 1470812 فیلتر نتایج به سال:
Targeted cancer therapies (TCT) are drugs that specifically act on molecular targets within the cancer cell causing its regression and/or death. Although TCT showed clinically important gains in survival within the indications that did not see any improvements in past, they also came at considerable cost. Different policies in drugs’ pricing and reimbursement among European countries that w...
he investigation by The BMJ and Cambridge and Bath universities into the availability of breakthrough hepatitis C drugs raises important questions for NHS England about access to lifesaving drugs. But why are medicines so expensive in the first place? The pricing strategy of Gilead for sofosbuvir (Sovaldi) and ledipasvir-sofosbuvir (Harvoni) raises questions that go well beyond the UK. The BMJ'...
بررسی تآثیر کورکومین بر بیان آکواپورین5 در سلول های سرطانی روده بزرگ انسان(ht-29) سرطان روده بزرگ جزو بیماری های خطرناک بوده و از نظر شیوع سومین سرطان شایع و دومین علت مرگ ومیر ناشی از سرطان در جهان محسوب می شود. خطرابتلا به این سرطان تحت تاثیر دو عامل محیطی وفاکتورهای ژنتیکی می باشد. آکواپورین ها، پروتئین های کانال آبی بوده که نقش مهمی را در انتقال آب در بافتهای اندوتلیالی و اپی تلیالی بر عهد...
Organizations are trying to address the high cost of "specialty" medications that treat conditions such as cancer, hepatitis C, and multiple sclerosis. While comprising less than 1% of U.S. prescriptions, these drugs now account for 27% of pharmacy spending.
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Recycling existing drugs for cancer therapy: delivering low cost c...
Long-term uninterrupted therapy is essential for maximizing clinical benefits of antiangiogenic drugs (AADs) in cancer patients. Unfortunately, nearly all clinically available AADs are delivered to cancer patients using disrupted regimens. We aim to develop lifetime, nontoxic, effective, orally active, and low-cost antiangiogenic and antitumor drugs for treatment of cancer patients. Here we rep...
Cancer patients are more susceptible to adverse drug-drug interactions (DDIs) due to receiving multiple medications especially chemotherapy medications, hormonal agents and supportive care drugs. The aim of this study is to describe the prevalence of potential DDIs and to identify risk factors for these potential interactions in hospitalized cancer patients in a developing country.A cross-secti...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید